Cytokine-Based Therapies And Inhibitors Market Report 2026

Cytokine-Based Therapies And Inhibitors Market Overview

• Cytokine-Based Therapies And Inhibitors market size has reached to $146.95 billion in 2025 • Expected to grow to $180.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Growing Incidences Of Autoimmune Disorders Fueling The Growth Of The Market Due To Increasing Demand For Immune-Modulating Therapies • Market Trend: Innovative Cytokine-Based Therapy With Intravesical Maintenance Immunotherapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cytokine-Based Therapies And Inhibitors Market?

Cytokine-based therapies and inhibitors refer to medical treatments that either enhance or block the activity of cytokines, small proteins involved in regulating immune responses, inflammation, and cell communication. These therapies are used to treat a range of conditions, including cancer, autoimmune diseases, and inflammatory disorders, by modulating immune system activity. The main types of cytokine-based therapies and inhibitors are interleukins, tumor necrosis factor, epidermal growth factor, interferon, and chemokine. Interleukins are cytokine proteins produced by immune cells that help regulate immune responses, inflammation, and cell signaling. These therapies are utilized in various applications such as cancer and malignancies, inflammatory and immune disorders, infectious diseases, asthma and airway inflammation, and others by various end users, including hospitals, clinics, research laboratories, academic and research institutes, specialty centers, and others.

What Is The Cytokine-Based Therapies And Inhibitors Market Growth Forecast?

The cytokine-based therapies and inhibitors market size is expected to see steady growth in the next few years. It will grow to $180.3 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to advances in recombinant cytokine engineering, rising investment in immuno-oncology and inflammatory disorder treatments, integration of AI for drug discovery, growing biopharmaceutical manufacturing infrastructure, expansion of clinical trials and personalized medicine initiatives. Major trends in the forecast period include rising adoption of cytokine-based therapies in oncology, expansion of targeted immune modulation therapies, growth in biopharmaceutical research and clinical trials, increasing focus on personalized medicine and precision therapies, enhanced regulatory and safety compliance in drug development.

Global Cytokine-Based Therapies And Inhibitors Market Segmentation

1) By Type: Interleukins, Tumor Necrosis Factor, Epidermal Growth Factor, Interferon, Chemokine 2) By Application: Cancer And Malignancies, Inflammatory And Immune Disorders, Infectious Diseases, Asthma And Airway Inflammation, Other Applications 3) By End User: Hospitals, Clinics, Research Laboratories, Academic And Research Institutes, Specialty Centers, Other End Users Subsegments: 1) By Interleukins: Interleukin-2, Interleukin-6, Interleukin-10, Interleukin-12, Interleukin-17, Interleukin-23 2) By Tumor Necrosis Factor (TNF): Tumor Necrosis Factor-Alpha Inhibitors, Tumor Necrosis Factor-Beta Inhibitors 3) By Epidermal Growth Factor (EGF): Epidermal Growth Factor Receptor Inhibitors, Human Epidermal Growth Factor Receptor 2 Inhibitors 4) By Interferon: Interferon-Alpha, Interferon-Beta, Interferon-Gamma 5) By Chemokine: C-C Chemokine Receptor Type 5 Antagonists, C-X-C Chemokine Receptor Type 4 Inhibitors, C-X-C Chemokine Receptor Type 1/2 Inhibitors

What Is The Driver Of The Cytokine-Based Therapies And Inhibitors Market?

The growing incidences of autoimmune disorders are expected to propel the growth of the cytokine-based therapies and inhibitors market going forward. Autoimmune disorders refer to conditions in which the body's immune system mistakenly attacks its healthy cells and tissues, perceiving them as foreign invaders. The rise in autoimmune disorders is due to changes in diet, particularly the increasing consumption of highly processed foods, which can disrupt gut microbiota and weaken immune regulation. Cytokine-based therapies and inhibitors help modulate the immune response by targeting specific cytokines involved in inflammation, making them effective in managing autoimmune disorders. For instance, in February 2024, according to the Arthritis Australia, an Australia-based non-profit organization, an estimated 562,378 Australians will be living with RA in 2025, accounting for 14% of all arthritis cases that year. By 2040, this number is expected to rise by 33% to 748,721 people. This represents an additional 186,343 Australians living with RA in 2040 compared with 2025. Therefore, the growing incidence of autoimmune disorders is driving the growth of the cytokine-based therapies and inhibitors industry.

Key Players In The Global Cytokine-Based Therapies And Inhibitors Market

Major companies operating in the cytokine-based therapies and inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc, UCB S.A., Biocon Limited.

Global Cytokine-Based Therapies And Inhibitors Market Trends and Insights

Major companies operating in the cytokine-based therapy and inhibitor market are focusing on innovative therapies such as intravesical cytokine maintenance immunotherapy to improve the durability of complete responses and reduce recurrence rates in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (BCG-unresponsive NMIBC). Intravesical cytokine maintenance immunotherapy involves the direct administration of immune-activating proteins into the bladder, followed by long-term maintenance dosing to continuously stimulate local immune responses and suppress tumor regrowth. For instance, in April 2024, the Food and Drug Administration, a US-based government regulatory authority, approved nogapendekin alfa inbakicept-pmln (Anktiva), a novel cytokine-based therapy approved by the Food and Drug Administration (FDA) for use in combination with Bacillus Calmette-Guérin (BCG). It is an advanced immunotherapy that functions as a fusion protein targeting interleukin-15 (IL-15) pathways, thereby activating CD122-positive immune cells such as natural killer (NK) cells and CD8-positive T cells. This mechanism aligns with the principles of cytokine-based therapy, which utilizes signaling proteins such as IL-15 to enhance the body’s immune surveillance and anti-tumor activity.

What Are Latest Mergers And Acquisitions In The Cytokine-Based Therapies And Inhibitors Market?

In May 2024, Vertex Pharmaceuticals Incorporated, a US-based biotechnology company, acquired Alpine Immune Sciences, Inc. for approximately $4.9 billion in cash. With this acquisition, Vertex aims to strengthen its immunology capabilities by integrating Alpine’s protein engineering platform and its lead candidate, povetacicept, to target serious autoimmune and kidney diseases. Alpine Immune Sciences Inc. is a US-based clinical stage biotech company focused on developing novel, protein-based immunotherapies.

Regional Insights

North America was the largest region in the cytokine-based therapies and inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cytokine-Based Therapies And Inhibitors Market?

The cytokine-based therapies and inhibitors market consists of revenues earned by entities providing services such as the development, manufacturing, and commercialization of cytokine-targeted drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine-based therapies and inhibitors market includes sales of products such as colony-stimulating factors, transforming growth factors, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cytokine-Based Therapies And Inhibitors Market Report 2026?

The cytokine-based therapies and inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine-based therapies and inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.